These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 31544849)

  • 21. Design Principles for Bispecific IgGs, Opportunities and Pitfalls of Artificial Disulfide Bonds.
    Vaks L; Litvak-Greenfeld D; Dror S; Shefet-Carasso L; Matatov G; Nahary L; Shapira S; Hakim R; Alroy I; Benhar I
    Antibodies (Basel); 2018 Jul; 7(3):. PubMed ID: 31544879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
    Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
    Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.
    Ahamadi-Fesharaki R; Fateh A; Vaziri F; Solgi G; Siadat SD; Mahboudi F; Rahimi-Jamnani F
    Mol Ther Oncolytics; 2019 Sep; 14():38-56. PubMed ID: 31011631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
    Igawa T
    Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
    Lu D; Zhu Z
    Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
    Lu D; Jimenez X; Zhang H; Bohlen P; Witte L; Zhu Z
    J Immunol Methods; 2002 Sep; 267(2):213-26. PubMed ID: 12165442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies.
    Bhatta P; Humphreys DP
    Antibodies (Basel); 2018 Aug; 7(3):. PubMed ID: 31544885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.
    Schaefer W; Völger HR; Lorenz S; Imhof-Jung S; Regula JT; Klein C; Mølhøj M
    MAbs; 2016; 8(1):49-55. PubMed ID: 26496506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The manufacturing considerations of bispecific antibodies.
    Underwood DJ; Bettencourt J; Jawad Z
    Expert Opin Biol Ther; 2022 Aug; 22(8):1043-1065. PubMed ID: 35771976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering IgG-Like Bispecific Antibodies-An Overview.
    Krah S; Kolmar H; Becker S; Zielonka S
    Antibodies (Basel); 2018 Aug; 7(3):. PubMed ID: 31544880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
    Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
    Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The making of bispecific antibodies.
    Brinkmann U; Kontermann RE
    MAbs; 2017; 9(2):182-212. PubMed ID: 28071970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.
    Husain B; Ellerman D
    BioDrugs; 2018 Oct; 32(5):441-464. PubMed ID: 30132211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.